about
Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: relation to autoantibody status and comparison with Belgian patients.Contribution of the TCF7L2 rs7903146 (C/T) gene polymorphism to the susceptibility to type 2 diabetes mellitus in Cameroon.Association between the TCF7L2 rs12255372 (G/T) gene polymorphism and type 2 diabetes mellitus in a Cameroonian population: a pilot study.Association between the rs12255372 variant of the TCF7L2 gene and obesity in a Cameroonian population.A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descentThe emerging era of pharmacogenomics: current successes, future potential, and challenges.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population.KCNT1 mutations in ADNFLE and MMPSI: a new driver in the etiology and pathophysiology of early-onset epileptic syndromes.HINT1 mutations define a novel disease entity - autosomal recessive axonal neuropathy with neuromyotonia.WDR45 mutations define a novel disease entity--static encephalopathy of childhood with neurodegeneration in adulthood.TNFa microsatellite polymorphism modulates the risk of type 1 diabetes in the Belgian population, independent of HLA-DQ.PDGFRB mutation causes autosomal-dominant Penttinen syndrome.Pharmacogenomic diversity in Singaporean populations and Europeans.EIF2AK4 genetic mutations cause a recessive form of rare and deadly lung disease, pulmonary veno-occlusive disease.Neither an intronic CA repeat within the CD48 gene nor the HERV-K18 polymorphisms are associated with type 1 diabetesMICA is associated with type 1 diabetes in the Belgian population, independent of HLA-DQIFIH1 gene polymorphisms in type 1 diabetes: genetic association analysis and genotype-phenotype correlation in the Belgian populationDLL4 loss-of-function heterozygous mutations cause Adams-Oliver syndromeUsing pharmacogenetics in real time to guide therapy: the warfarin exampleGFI1B mutation causes autosomal dominant gray platelet syndrome
P50
Q33995773-54AE383F-6170-4E32-9D7C-253D032B2FA8Q35494197-5152967C-CE89-4836-9C86-BAAB07C67F69Q35614462-DE08ADF5-4A84-49B1-AE57-8E8532DB2402Q35853323-B931DCA9-7CAD-4101-9864-166942BFF30EQ36004460-034A9244-D83E-44F4-9A44-55816286D59FQ36384257-3576FA25-7FCF-48FA-9FC8-1E58A8095B28Q38200683-D89E5E7B-DC2C-4ABF-A15D-855ABDB36C0BQ38838517-2264A2B2-0E70-426C-812C-8D6C6172E8B3Q42696912-24C22FF8-42FC-4451-8E8A-DF7417A670B0Q42904552-D75B1EF2-78D6-4D8C-ADE5-C7E5167C80B2Q45022179-F13E2919-4F2E-4520-BA72-B5E2DE6FF723Q45767747-A177525E-FCAD-4E18-8502-A43AD2CD449DQ45835004-216EF8EE-019F-48A0-B18A-C1C4AA833213Q51743340-222EC716-8C0F-42AC-B2FA-32CF681625A4Q53298268-00BD103D-D276-4692-BB7E-28261C4BA3E0Q53541756-7AD9F53D-16BD-491F-9B72-789C90B67F4FQ54342386-9A9F0763-4FAB-41EA-A581-2ECE64DD6B7AQ79983948-97DCE27F-5008-473D-9C2A-810A4DE00655Q83336456-F1A101EA-11E9-438D-AA6E-A5CF8ECB4FE4Q84088337-DEA96450-3838-4154-8C2B-4E8B6DF90064Q86317839-C152918F-DD53-4475-84C4-CAFC41309744Q87440996-FEFA1F87-D136-417E-85A7-BFB872A85364Q87454755-22D8D33E-9272-4066-816A-2A7F742D2B94
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Folefac Aminkeng
@ast
Folefac Aminkeng
@en
Folefac Aminkeng
@es
Folefac Aminkeng
@nl
type
label
Folefac Aminkeng
@ast
Folefac Aminkeng
@en
Folefac Aminkeng
@es
Folefac Aminkeng
@nl
prefLabel
Folefac Aminkeng
@ast
Folefac Aminkeng
@en
Folefac Aminkeng
@es
Folefac Aminkeng
@nl
P106
P31
P496
0000-0001-8916-9758